(Q37504664)

20 August 2017

1 reference

title

Cardiovascular and metabolic complications during androgen deprivation: exercise as a potential countermeasure (English)

1 reference

20 August 2017

1 reference

D A Galvão

1

1 reference

20 August 2017

D R Taaffe

2

1 reference

20 August 2017

N Spry

3

1 reference

20 August 2017

D Joseph

4

1 reference

20 August 2017

R U Newton

5

1 reference

20 August 2017

publication date

2 June 2009

1 reference

Prostate Cancer and Prostatic Diseases

20 August 2017

published in

1 reference

20 August 2017

volume

12

1 reference

20 August 2017

issue

3

1 reference

20 August 2017

page(s)

233-240

1 reference

Physical activity and reduced occurrence of non-insulin-dependent diabetes mellitus

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.12

Physical activity and coronary heart disease risk in men: does the duration of exercise episodes predict risk?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.12

AHA Science Advisory. Resistance exercise in individuals with and without cardiovascular disease: benefits, rationale, safety, and prescription: An advisory from the Committee on Exercise, Rehabilitation, and Prevention, Council on Clinical Cardiolo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.12

Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.12

Androgen deprivation therapy for prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.12

Risk of fracture after androgen deprivation for prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.12

Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.12

Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.12

Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.12

Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.12

Influence of Androgen Suppression Therapy for Prostate Cancer on the Frequency and Timing of Fatal Myocardial Infarctions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.12

Insulin sensitivity during combined androgen blockade for prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.12

Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.12

Lipoprotein profile in men with prostate cancer undergoing androgen deprivation therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.12

Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.12

Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.12

Serum testosterone recovery after cessation of long-term luteinizing hormone-releasing hormone agonist in patients with prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.12

Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.12

Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.12

Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.12

Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.12

Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.12

Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.12

Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.12

Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.12

Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.12

Low bone density and high percentage of body fat among men who were treated with androgen deprivation therapy for prostate carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.12

Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.12

Glucose intolerance during hormonal therapy for prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.12

Testosterone suppression in men with prostate cancer is associated with increased arterial stiffness

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.12

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.12

Physical fitness as a predictor of cardiovascular mortality in asymptomatic North American men. The Lipid Research Clinics Mortality Follow-up Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.12

Exercise capacity and mortality among men referred for exercise testing.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.12

Influence of physical training on blood glucose control, glucose tolerance, insulin secretion, and insulin action in non-insulin-dependent diabetic patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.12

Comparison of lifestyle and structured interventions to increase physical activity and cardiorespiratory fitness: a randomized trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.12

Work Activity and Coronary Heart Mortality

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.12

Changes in physical activity, mortality, and incidence of coronary heart disease in older men

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.12

Associations of light, moderate, and vigorous intensity physical activity with longevity. The Harvard Alumni Health Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.12

Physical activity and coronary heart disease in men: The Harvard Alumni Health Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.12

Association between muscular strength and mortality in men: prospective cohort study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.12

Association of muscular strength with incidence of metabolic syndrome in men.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.12

Associations of muscle strength and fitness with metabolic syndrome in men.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.12

Comparative effects of high- and low-intensity resistance training on thigh muscle strength, fiber area, and tissue composition in elderly women

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.12

High-intensity strength training in nonagenarians. Effects on skeletal muscle

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.12

Resistance exercise in individuals with and without cardiovascular disease: 2007 update: a scientific statement from the American Heart Association Council on Clinical Cardiology and Council on Nutrition, Physical Activity, and Metabolism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.12

Exercise can prevent and even reverse adverse effects of androgen suppression treatment in men with prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.12

Role of resistance training in heart disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.12

Battling insulin resistance in elderly obese people with type 2 diabetes: bring on the heavy weights

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.12

American College of Sports Medicine position stand. Exercise and type 2 diabetes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.12

ACSM Position Stand: The Recommended Quantity and Quality of Exercise for Developing and Maintaining Cardiorespiratory and Muscular Fitness, and Flexibility in Healthy Adults

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.12

Resistance Exercise in Men Receiving Androgen Deprivation Therapy for Prostate Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.12

Endocrine and immune responses to resistance training in prostate cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.12

Resistance Training and Reduction of Treatment Side Effects in Prostate Cancer Patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.12

Association of Long-Distance Corridor Walk Performance With Mortality, Cardiovascular Disease, Mobility Limitation, and Disability

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.12

Measuring Fitness in Healthy Older Adults: The Health ABC Long Distance Corridor Walk

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.12

Estimating cardiorespiratory fitness in well-functioning older adults: treadmill validation of the long distance corridor walk

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.12

Androgen deprivation therapy and cardiac function: effects of endurance training

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.12

Reduced central blood pressure in older adults following progressive resistance training

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.12

Review of exercise intervention studies in cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.12

Exercise in Cancer Survivors: An Overview of Research

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.12

Long-term effects of androgen deprivation therapy in prostate cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.12

The influence of androgen deprivation therapy on metabolism in patients with prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.12

31 March 2020

Identifiers

DOI

10.1038/PCAN.2009.12

1 reference

Dimensions Publication ID

20 August 2017

1045996043

0 references

1 reference